VivoSeq
Oncology

Fallopian Tube Neoplasm

2

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Fallopian Tube Neoplasm is an early-stage landscape with 2 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

N/A

Pipeline

Programs by Phase

Preclinical2

Mirvetuximab Soravtansine

Immunogenics, LLC

Bevacizumab

Bio-Thera Solutions

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Monoclonal antibody150%
Antibody–drug conjugate150%

Modality classified for 100% of 2 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)